Futura’s innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.
We focus exclusively on topically applied pharmaceutical drugs and medical devices. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.
In addition to our developing portfolio of sexual healthcare and pain relief products we are looking at incorporating our proprietary delivery system DermaSys® into other products that may fall outside of these current areas provided that we believe they offer a compelling commercial opportunity. This is the case for our product for cellulite reduction CRF100.
We have five products in our development pipeline for sexual healthcare and pain relief: CSD500, PET500, MED2002, TPR100 and CRF100.
To view our product pipeline, follow this link.